Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
!["Illustration of Dupixent Treatment"](https://wellnessnews24.com/wp-content/uploads/2024/02/pexels-photo-5857416.webp)
2 min read
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare...